A naukri.com initiative
Bioengineer
4d
346
Image Credit: Bioengineer
Platelet-Neutrophil-Monocyte-Lymphocyte Ratio Predicts Renal Cancer Outcomes
- A novel prognostic indicator, the platelet-neutrophil-monocyte-lymphocyte ratio (PNMLR), has emerged for survival outcomes in non-metastatic renal cell carcinoma patients post-nephrectomy.
- PNMLR integrates platelets, neutrophils, monocytes, and lymphocytes to offer a comprehensive inflammatory profile in RCC, surpassing traditional indices like NLR and PLR.
- A study on 1163 surgically treated non-metastatic RCC patients revealed that elevated PNMLR correlates with aggressive tumor characteristics and poorer prognoses.
- Propensity score matching validated PNMLR's prognostic relevance, showing higher risks of relapse and mortality for patients with elevated PNMLR levels.
- PNMLR demonstrated competitive predictive performance for disease-free survival and overall survival, reflecting critical tumor-associated inflammation not captured by conventional markers.
- Despite its moderate discriminative capacity, PNMLR should complement existing clinical parameters in prognostic frameworks for RCC to enhance patient risk stratification.
- The study suggests external validation of PNMLR in diverse cohorts and ongoing monitoring during patient follow-up to guide post-operative surveillance and therapeutic decisions in RCC.
- The PNMLR's integration into clinical workflows could refine prognostic algorithms, inform trial designs, and potentially lead to anti-inflammatory strategies to enhance RCC management.
- Collaborative multidisciplinary efforts are essential for standardizing PNMLR measurement protocols and maximizing its utility in personalized care for non-metastatic RCC patients.
- The PNMLR represents a significant advancement in inflammation-based cancer prognostication by capturing the complex interplay between systemic inflammation and cancer outcomes.
Read Full Article
20 Likes
For uninterrupted reading, download the app